The Online Investor
Diagnostics M&A image Diagnostics M&A » By The Online Investor Staff, updated Wed., Sep. 23, 4:34 AM Recent mergers and acquisitions in the Diagnostics M&A category.

Slide #24. BioTelemetry, Inc. Mednet Healthcare Technologies, Inc.

Acquirer: BioTelemetry, Inc. (NASDAQ:BEAT)
Acquiree: Mednet Healthcare Technologies, Inc.
Details: BioTelemetry, Inc. (Nasdaq:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today a significant victory in the patent infringement case against Mednet Healthcare Technologies, Inc. and its subsidiaries, Heart-Care Corporation of America, Universal Medical Inc., and Universal Medical Laboratory, Inc. ("Mednet"), as well as other named defendants. Mednet entered into a consent judgment, declaring that the Mednet entities infringed on five patents owned by BioTelemetry and its subsidiary, Braemar Manufacturing, and that all five patents are valid.

BioTelemetry is a remote medical technology company focused on delivery of health information. Co. provides remote cardiac monitoring, centralized core laboratory services, remote blood glucose monitoring, and original equipment manufacturing that serves both healthcare and clinical research customers. Co.'s segments are: Healthcare, which is focused on remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders and to monitor the functionality of implantable cardiac devices; and Research, which is engaged in centralized core laboratory services providing cardiac monitoring, imaging services, consulting and data management services for drug and medical device trials.

BEAT SEC Filing Email Alerts Service

Open the BEAT Page at The Online Investor »

Company Name: 
BioTelemetry Inc
Number of ETFs Holding BEAT: 
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 

Open the BEAT Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Buy (3.00 out of 4)
40th percentile
(ranked lower than approx. 60% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Diagnostics M&A - Slide 24 of 100 Page |

Copyright © 1998 - 2020, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.